Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2 (1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: The present technology pertains to synchronized video viewing that is supported by the use of a pending changes count to keep the client devices in synchronization while providing a user experience that matches the expectations of the user. A second client device can receive input to change some aspect of the playback of a video that is being viewed synchronously with at least one other device. The second client device can process the event so the video can reflect the received input. The second client device can also send a collaboration message to a synchronized video viewing service to inform other client devices of the command. Since the second client device is aware of its own event, the second client device can ignore processing any other collaboration messages until it receives the collaboration message it initiated echoed back to it. Thereafter it can resume processing received collaboration messages.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: The present technology pertains to synchronized video viewing that is supported by the use of a pending changes count to keep the client devices in synchronization while providing a user experience that matches the expectations of the user. A second client device can receive input to change some aspect of the playback of a video that is being viewed synchronously with at least one other device. The second client device can process the event so the video can reflect the received input. The second client device can also send a collaboration message to a synchronized video viewing service to inform other client devices of the command. Since the second client device is aware of its own event, the second client device can ignore processing any other collaboration messages until it receives the collaboration message it initiated echoed back to it. Thereafter it can resume processing received collaboration messages.

Abstract: The present technology pertains to synchronized video viewing that is supported by the use of a pending changes count to keep the client devices in synchronization while providing a user experience that matches the expectations of the user. A second client device can receive input to change some aspect of the playback of a video that is being viewed synchronously with at least one other device. The second client device can process the event so the video can reflect the received input. The second client device can also send a collaboration message to a synchronized video viewing service to inform other client devices of the command. Since the second client device is aware of its own event, the second client device can ignore processing any other collaboration messages until it receives the collaboration message it initiated echoed back to it. Thereafter it can resume processing received collaboration messages.

Abstract: The present technology pertains to synchronized video viewing that is supported by the use of a pending changes count to keep the client devices in synchronization while providing a user experience that matches the expectations of the user. A second client device can receive input to change some aspect of the playback of a video that is being viewed synchronously with at least one other device. The second client device can process the event so the video can reflect the received input. The second client device can also send a collaboration message to a synchronized video viewing service to inform other client devices of the command. Since the second client device is aware of its own event, the second client device can ignore processing any other collaboration messages until it receives the collaboration message it initiated echoed back to it. Thereafter it can resume processing received collaboration messages.

Abstract: Disclosed are a pair of gloves having weights rigidly attached to outer surfaces of fingers and palm. The fingers may be partially cut off or have removable tips. At least several of the fingertips having crush resistant caps embedded within the outer layer of the fabric. A user may utilize touchscreen technology without remove the gloves as the outer layer of the gloves and liner are embedded with current conductive threading.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.